Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | DHCR24 | Q15392 | 11/20 | 0.74 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
| ▸ | RORC | P51449 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL847506 | 1.00 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL24300840 | 1.00 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL188329 | 1.00 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL335521 | 1.00 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL30650209 | 0.93 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL9155413 | 0.90 | RORC (0.80) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL7624350 | 0.89 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL15123702 | 0.89 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL14911153 | 0.87 | ALDH1A1 (0.80) | ALDH1A1MEN1KMT2AUSP2MAPT | |
| SCHEMBL1237838 | 0.85 | ALDH1A1 (0.77) | ALDH1A1MEN1KMT2AUSP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075388-A | Ophthalmic compositions for treating vision disorders | — | 2026-05-26 | — | — | CN | claimed |
| EP-4382098-A1 | OPHTHALMIC COMPOSITION FOR THE TREATMENT OF VISUAL DISORDERS | Foodvica, S.A. De C.V. (MX) | 2024-06-12 | — | — | EP | claimed |
| US-20170027961-A1 | COMPOSITIONS FOR THE TREATMENT OF CATARACTS | Catacore, Inc. (US) | 2017-02-02 | — | — | US | claimed |
| EP-0636139-B1 | ISOLATION OF STEROIDS CONTAINING A 5,7-DIENE FUNCTIONALITY FROM A STEROL MIXTURE | STANFORD RES INST INT (US) | 1999-11-17 | — | — | EP | claimed |
| US-5391777-A | Isolation of steroids containing a 5,7-diene functionality from a sterol mixture | SRI INTERNATIONAL (US) | 1995-02-21 | — | — | US | claimed |
| EP-0636139-A1 | ISOLATION OF STEROIDS CONTAINING A 5,7-DIENE FUNCTIONALITY FROM A STEROL MIXTURE | SRI INTERNATIONAL (US) | 1995-02-01 | — | — | EP | claimed |
| CN-118973585-A | DHCR24 inhibiting compounds | 莱顿教学医院 | 2024-11-15 | — | — | CN | disclosed |
| US-12023318-B2 | Therapy for Inflammatory Linear Verrucous Epidermal Nevus (ILVEN) | UCL BUSINESS LTD (GB) | 2024-07-02 | — | — | US | disclosed |
| EP-4382098-A1 | OPHTHALMIC COMPOSITION FOR THE TREATMENT OF VISUAL DISORDERS | Foodvica, S.A. De C.V. (MX) | 2024-06-12 | — | — | EP | disclosed |
| US-20230033795-A1 | NEW THERAPY | UCL BUSINESS LTD (GB) | 2023-02-02 | — | — | US | disclosed |
| US-10398709-B2 | Compositions for the treatment of cataracts | Catacore, Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10398709-B2 | Compositions for the treatment of cataracts | Catacore, Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10308971-B2 | Microorganism for expressing a human membrane protein | NOVOZYMES A/S (DK) | 2019-06-04 | — | — | US | disclosed |
| US-6225075-B1 | DNA encoding sterol methyltransferase | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2001-05-01 | — | — | US | disclosed |
| EP-1067939-A1 | USE OF STEROIDAL ALKALOID DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAYS | The Johns Hopkins University, School of Medicine, Office of Technology Licencing (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0636139-B1 | ISOLATION OF STEROIDS CONTAINING A 5,7-DIENE FUNCTIONALITY FROM A STEROL MIXTURE | STANFORD RES INST INT (US) | 1999-11-17 | — | — | EP | disclosed |
| WO-1999052534-A1 | USE OF STEROIDAL ALKALOID DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAYS | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1999-10-21 | — | — | WO | disclosed |
| US-5391777-A | Isolation of steroids containing a 5,7-diene functionality from a sterol mixture | SRI INTERNATIONAL (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0636139-A1 | ISOLATION OF STEROIDS CONTAINING A 5,7-DIENE FUNCTIONALITY FROM A STEROL MIXTURE | SRI INTERNATIONAL (US) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021204-A1 | METHOD FOR PREPARING CHOLESTA-5,7-DIENE-3-BETA,25-DIOL AND ANALOGS THEREOF | SRI INTERNATIONAL (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033795-A1 | NEW THERAPY | HMGCR, CYP46A1, DHCR7 | ALDH1A1 889/4885MEN1 4657/4885KMT2A 3555/4885 |
| US-20170027961-A1 | COMPOSITIONS FOR THE TREATMENT OF CATARACTS | CYP46A1, DHCR7, NR1H3 | ALDH1A1 1739/4885MEN1 3838/4885KMT2A 4239/4885 |
| US-10398709-B2 | Compositions for the treatment of cataracts | CYP46A1, DHCR7, NR1H3 | ALDH1A1 1739/4885MEN1 3838/4885KMT2A 4239/4885 |
| US-12023318-B2 | Therapy for Inflammatory Linear Verrucous Epidermal Nevus (ILVEN) | HMGCR, LDLR, HMGB2 | ALDH1A1 842/4885MEN1 1900/4885KMT2A 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.